TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune®PRNewsWire • 09/13/22
TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 08/22/22
TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022"PRNewsWire • 07/08/22
TC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise GloballyPRNewsWire • 05/31/22
Kuick Research Recognizes TC BioPharm as a Key Player in the Gamma-Delta T Cell Therapy MarketPRNewsWire • 05/23/22
TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy ExpertsPRNewsWire • 05/18/22
TC BioPharm Donates to Leukemia and Lymphoma Society in Sponsorship of World AML DayPRNewsWire • 04/21/22
TC BioPharm Announces Initiation of Equity Analyst Coverage by EF Hutton with a "Buy" RecommendationPRNewsWire • 03/29/22
TC BioPharm Receives MHRA and Research Ethics Committee Approvals to Initiate Phase 2B/3 Clinical Trials for the Treatment of Acute Myeloid LeukemiaPRNewsWire • 03/23/22
TC BioPharm Announces Positive Phase 1b/2a Data in Late-Stage Acute Myeloid Leukemia Patients Treated with Allogeneic Gamma Delta T CellsPRNewsWire • 03/08/22